Scandinavian journal of gastroenterology · 2026
Factors associated with mesalamine refractory ulcerative proctitis requiring advanced medical treatments.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Borkovsky Tom, Cohen Nathaniel Aviv, Shoam Ori, Bannon Lian, Hirsch Ayal, Ron Yulia, Thurm Tamar, Maharshak Nitsan, Leibovitzh Haim
Аннотация
BACKGROUND: Ulcerative proctitis (UP) is a subtype of ulcerative colitis (UC) affecting the rectum, usually manageable with mesalamine. However, a subgroup of patients is refractory to mesalamine, necessitating advanced therapies. We aimed to assess risk factors for refractory disease.
MATERIALS AND METHODS: Data on proctitis patients were collected retrospectively from a single tertiary center during 2010-2024. Proctitis was defined as maximal disease extent of 20 cm from the anal verge. Patients treated with immunomodulators and/or biological therapy were considered to have refractory proctitis. Multivariable logistic regression analysis was used to identify risk factors.
RESULTS: We included 230 patients in the analysis, of whom 50 (21.7%) patients had refractory disease. At diagnosis, refractory patients were younger (25.0 years [20.0-32.0] vs. 30.5 years [22.5-41.0], p = 0.008), had longer disease extent (12.37 cm ± 5.81 vs. 9.87 cm ± 5.40, p = 0.018), had more severe endoscopic activity (Mayo endoscopic score [MES] 2/3: 21 [87.5%] vs. 45 [59.2%], p = 0.025) and more often used rectal steroids (24 [48.9%] vs. 31 [17.3%], p = 0.009). There was no difference between groups in sex, BMI, smoking status, presence of cecal patch, use of rectal 5-ASA or follow-up duration. In the multivariable regression model, the only significant predictors were use of topical steroids (odds ratio 4.0, 95% CI 1.13-14.13, p = 0.031) and baseline endoscopic severity (odds ratio 5.23, 95% CI 1.04-26.27, p = 0.044).
CONCLUSIONS: The use of topical steroids and endoscopic disease severity at diagnosis were associated with refractory proctitis. These results may help stratify patients who could benefit from closer, tailored monitoring strategies.
MATERIALS AND METHODS: Data on proctitis patients were collected retrospectively from a single tertiary center during 2010-2024. Proctitis was defined as maximal disease extent of 20 cm from the anal verge. Patients treated with immunomodulators and/or biological therapy were considered to have refractory proctitis. Multivariable logistic regression analysis was used to identify risk factors.
RESULTS: We included 230 patients in the analysis, of whom 50 (21.7%) patients had refractory disease. At diagnosis, refractory patients were younger (25.0 years [20.0-32.0] vs. 30.5 years [22.5-41.0], p = 0.008), had longer disease extent (12.37 cm ± 5.81 vs. 9.87 cm ± 5.40, p = 0.018), had more severe endoscopic activity (Mayo endoscopic score [MES] 2/3: 21 [87.5%] vs. 45 [59.2%], p = 0.025) and more often used rectal steroids (24 [48.9%] vs. 31 [17.3%], p = 0.009). There was no difference between groups in sex, BMI, smoking status, presence of cecal patch, use of rectal 5-ASA or follow-up duration. In the multivariable regression model, the only significant predictors were use of topical steroids (odds ratio 4.0, 95% CI 1.13-14.13, p = 0.031) and baseline endoscopic severity (odds ratio 5.23, 95% CI 1.04-26.27, p = 0.044).
CONCLUSIONS: The use of topical steroids and endoscopic disease severity at diagnosis were associated with refractory proctitis. These results may help stratify patients who could benefit from closer, tailored monitoring strategies.